Literature DB >> 8586458

Histopathology, classification, and grading of gliomas.

P Kleihues1, F Soylemezoglu, B Schäuble, B W Scheithauer, P C Burger.   

Abstract

Neoplastic transformation occurs in all glial cell types of the human nervous system, producing a wide variety of clinico-pathological entities and morphological variants. Astrocytomas are most common and span an unusually wide spectrum, ranging from the slowly growing juvenile pilocytic astrocytoma to the highly malignant glioblastoma multiforme. Diffusely infiltrating astrocytomas of the cerebral hemispheres show an inherent tendency for progression towards a more malignant phenotype. This change is morphologically categorized in histologic grading schemes (e.g., WHO Grade II to IV) and is associated with the sequential acquisition of genetic alterations, including mutations in the p53 and homozygous deletions of the p16 tumour suppressor genes. Loss of heterozygosity on chromosomes 10 and 19q as well as amplification of the EGF receptor are largely restricted to malignant gliomas and thus considered late events in astrocytoma progression. Gliomas often show phenotypic expression of different glial cell lineages (e.g., oligoastrocytoma). Recent studies suggest that the occurrence of mixed gliomas is not indicative of a polyclonal origin but rather reflects altered gene expression, leading to a change in the balance of growth factors influencing glioma differentiation.

Entities:  

Mesh:

Year:  1995        PMID: 8586458     DOI: 10.1002/glia.440150303

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  88 in total

Review 1.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

2.  Prognostic value of histological features in diffuse astrocytomas WHO grade II.

Authors:  Tove Lind-Landström; Andreas Hanssøn Habberstad; Stein Sundstrøm; Sverre Helge Torp
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

3.  Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors.

Authors:  Meng Law; Khuram Kazmi; Stephan Wetzel; Edwin Wang; Codrin Iacob; David Zagzag; John G Golfinos; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 4.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

5.  Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature.

Authors:  Brent A Orr; Charles G Eberhart
Journal:  Am J Pathol       Date:  2012-03-23       Impact factor: 4.307

6.  In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas.

Authors:  R Jain; J Gutierrez; J Narang; L Scarpace; L R Schultz; N Lemke; S C Patel; T Mikkelsen; J P Rock
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-11       Impact factor: 3.825

7.  Whole-brain N-acetylaspartate spectroscopy and diffusion tensor imaging in patients with newly diagnosed gliomas: a preliminary study.

Authors:  M Inglese; S Brown; G Johnson; M Law; E Knopp; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

8.  Loss of heterozygosity of the APC gene found in a single case of oligoastrocytoma.

Authors:  Nives Pecina-Slaus; Vili Beros; Karlo Houra; Hrvoje Cupic
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

9.  MTH-68/H oncolytic viral treatment in human high-grade gliomas.

Authors:  L K Csatary; G Gosztonyi; J Szeberenyi; Z Fabian; V Liszka; B Bodey; C M Csatary
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 10.  A role for glutamate in growth and invasion of primary brain tumors.

Authors:  Harald Sontheimer
Journal:  J Neurochem       Date:  2008-02-14       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.